- Not all acute colonic diverticulitis follows the same course: a potential risk for immunocompromised individuals
-
Park Y
- KMID: 2547190
- Intest Res.
- 2023 Oct;21(4):415-417.
- doi: 10.5217/ir.2023.00142
-
- CITED
-
- Close
- SHARE
-
- Close
- To overcome medical gap in screening and surveillance of colorectal cancer during the COVID-19 pandemic
-
Han YM
- KMID: 2547191
- Intest Res.
- 2023 Oct;21(4):418-419.
- doi: 10.5217/ir.2023.00144
-
- CITED
-
- Close
- SHARE
-
- Close
- Regional variations in the prevalence of primary sclerosing cholangitis associated with inflammatory bowel disease
-
Kim KW, Kang HW
- KMID: 2547189
- Intest Res.
- 2023 Oct;21(4):413-414.
- doi: 10.5217/ir.2023.00133
-
- CITED
-
- Close
- SHARE
-
- Close
- Treatment of primary sclerosing cholangitis combined with inflammatory bowel disease
-
Kim YS, Hurley EH, Park Y, Ko S
- KMID: 2547192
- Intest Res.
- 2023 Oct;21(4):420-432.
- doi: 10.5217/ir.2023.00039
Primary sclerosing cholangitis (PSC) is a progressive cholestatic, inflammatory, and fibrotic disease that is strongly associated with inflammatory bowel disease (IBD). PSC-IBD represents a unique disease entity and patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
-
Hwang SW, Kim MK, Kweon MN
- KMID: 2547193
- Intest Res.
- 2023 Oct;21(4):433-442.
- doi: 10.5217/ir.2023.00019
Immune checkpoint inhibitors have dramatically revolutionized the therapeutic landscape for patients with advanced malignancies. Recently, convincing evidence has shown meaningful influence of gut microbiome on human immune system. With the... -
- CITED
-
- Close
- SHARE
-
- Close
- Summary and comparison of recently updated post-polypectomy surveillance guidelines
-
Jung YS
- KMID: 2547194
- Intest Res.
- 2023 Oct;21(4):443-451.
- doi: 10.5217/ir.2023.00107
Recently, updated guidelines for post-polypectomy surveillance have been published by the U.S. Multi‐Society Task Force (USMSTF), the British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England... -
- CITED
-
- Close
- SHARE
-
- Close
- Low prevalence of primary sclerosing cholangitis in patients with inflammatory bowel disease in India
-
Singh A, Midha V, Narang V, Kedia S, Mahajan R, Dhoble P, Kahlon BK, Dhaliwal AS, Tripathi A, Kalra S, Jain NP, Bansal N, Banerjee R, Desai D, Dutta U, Ahuja V, Sood A
- KMID: 2547195
- Intest Res.
- 2023 Oct;21(4):452-459.
- doi: 10.5217/ir.2022.00087
Background/Aims: Primary sclerosing cholangitis (PSC) represents the most common hepatobiliary extraintestinal manifestation of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). Limited data exist on PSC... -
- CITED
-
- Close
- SHARE
-
- Close
- The elderly population are more vulnerable for the management of colorectal cancer during the COVID-19 pandemic: a nationwide, population-based study
-
Kang HS, Jeon SH, Park SB, Youn JY, Kwak MS, Cha JM
- KMID: 2547200
- Intest Res.
- 2023 Oct;21(4):500-509.
- doi: 10.5217/ir.2023.00004
Background/Aims: The impact of coronavirus disease 2019 (COVID-19) on the management of colorectal cancer (CRC) may worse in elderly population, as almost all COVID-19 deaths occurred in the elderly patients.... -
- CITED
-
- Close
- SHARE
-
- Close
- Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study
-
Nagata T, Funakoshi S, Morihara D, Shakado S, Yokoyama K, Takata K, Tanaka T, Fukunaga A, Yamauchi R, Fukuda H, Matsuoka H, Imakiire S, Sakisaka H, Matsuoka S, Kuno N, Abe K, Ishibashi H, Ashizuka S, Hirai F
- KMID: 2547197
- Intest Res.
- 2023 Oct;21(4):471-480.
- doi: 10.5217/ir.2023.00035
Background/Aims: The frequency and details of nonalcoholic fatty liver disease (NAFLD) complications in patients with inflammatory bowel disease (IBD) remain unclear. This study aimed to clarify characteristics of NAFLD in... -
- CITED
-
- Close
- SHARE
-
- Close
- How the COVID-19 pandemic affected the severity and clinical presentation of diverticulitis
-
Soliman SS, Rolandelli RH, Chang GC, Nemecz AK, Nemeth ZH
- KMID: 2547199
- Intest Res.
- 2023 Oct;21(4):493-499.
- doi: 10.5217/ir.2022.00042
Background/Aims: Single-institution studies showed that patients presented with more severe diverticulitis and underwent more emergency operations during the coronavirus disease 2019 (COVID-19) pandemic. Therefore, we studied this trend using nationwide... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical characteristics and risk factors related to polyposis recurrence and advanced neoplasm development among patients with non-hereditary colorectal polyposis
-
Jang J, Park J, Park SJ, Park JJ, Cheon JH, Kim TI
- KMID: 2547201
- Intest Res.
- 2023 Oct;21(4):510-517.
- doi: 10.5217/ir.2022.00139
Background/Aims: Patients with more than 10 cumulative polyps might involve a greater genetic risk of colorectal neoplasia development. However, few studies have investigated the risk factors of polyposis recurrence and... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative outcomes of acute colonic diverticulitis in immunocompromised versus immunocompetent patients: a systematic review and meta-analysis
-
Lee JG, Park YE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee SH, You MW, Kim SE
- KMID: 2547198
- Intest Res.
- 2023 Oct;21(4):481-492.
- doi: 10.5217/ir.2023.00005
Background/Aims: Immunocompromised patients with acute colonic diverticulitis are at high risk for complications and failure of non-surgical treatment. However, evidence on the comparative outcomes of immunocompromised and immunocompetent patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Serum albumin is the strongest predictor of anti-tumor necrosis factor nonresponse in inflammatory bowel disease in resource-constrained regions lacking therapeutic drug monitoring
-
Kumar P, Vuyyuru SK, Das P, Kante B, Ranjan MK, Thomas DM, Mundhra S, Sahu P, Venigalla PM, Jain S, Goyal S, Golla R, Virmani S, Singh MK, Sachdeva K, Sharma R, Dash NR, Makharia G, Kedia S, Ahuja V
- KMID: 2547196
- Intest Res.
- 2023 Oct;21(4):460-470.
- doi: 10.5217/ir.2022.00128
Background/Aims: Evidence on predictors of primary nonresponse (PNR), and secondary loss of response (SLR) to anti-tumor necrosis factor (anti-TNF) agents in inflammatory bowel disease is scarce from Asia. We evaluated... -
- CITED
-
- Close
- SHARE
-
- Close
